Determination of serum antibodies against swine-origin influenza A virus H1N1/09 by immunofluorescence, haemagglutination inhibition, and by neutralization tests: how is the prevalence rate of protecting antibodies in humans?
Determination of serum antibodies against swine-origin influenza A virus H1N1/09 by immunofluorescence, haemagglutination inhibition, and by neutralization tests: how is the prevalence rate of protecting antibodies in humans?
复制标题
DOI：
10.1007/s00430-010-0143-4
复制
发表时间：
2010-05-01
影响因子：
5.4
通讯作者：
Doerr, H. W.
中科院分区：
文献类型：
--
作者：
Allwinn, Regina;Geiler, Janina;Doerr, H. W.
2009年4月，甲型流感病毒的一种新变种H1N1 v亚型在墨西哥出现，并在1918-1920年和1978/1979年之后在全世界传播，在人类中产生H1N1大流行。显然，对这种新的病毒变种没有群体免疫力。主要是年轻人，但较少老年人受到影响，并提出了严重的，甚至致命的病程。由于病毒特异性抗体通常被认为是部分或完全免疫保护的标志物，我们在大流行到达我们地区之前和之后从人获得的血清样品中进行抗体测定（法兰克福/M.，德国）。通过间接免疫荧光法、中和试验和血凝抑制试验（HI）进行测定，HI是在通用和易于使用的实际修改中建立的。在145名在大流行爆发前抽取血清样本的人中，19人显示体液免疫，即H1N1 v中和抗体滴度（至少1：64）。其中11人年龄在60岁以上，1人属于40-59岁年龄组，3人属于20-39岁年龄组，2人属于15-19岁年龄组。在法兰克福大流行发生后，从我们当地大学医院随机选择的n = 225名患者中抽取血清样本，通过HI检测H1N1 v抗体，HI通常被推荐用于免疫常规检查。28名个体显示保护性抗体滴度至少为1：40。年龄分布已转向平均年龄组。结果符合甲型H1N1（09）流感的发病率，正如我们医院收治的患者中RT-PCR所证实的那样，在30岁以下的年轻年龄组中达到峰值（第二个受影响组：30-40岁）。虽然常用的固相抗体测试（如免疫荧光）不适合诊断通过H1N1（09）感染和获得性免疫，这可以很容易地通过HI完成。预计下一波甲型流感/H1N1 v感染，HI测试可能会避免在严重或隐藏不良反应的特殊风险下接种疫苗。
In April 2009, a new variant of influenza A virus, subtype H1N1v emerged in Mexico and spread all over the world producing the H1N1 pandemic in mankind after 1918-1920 and 1978/1979. Obviously there was no herd immunity against this new virus variant. Mainly young people, but less elderly were affected and presented severe and even lethal courses of disease. Since virus-specific antibodies are commonly regarded as markers of partial or complete immunoprotection, we performed antibody determinations in serum samples obtained from people before and after the pandemic has arrived in our region (Frankfurt/M., Germany). The assays were done by indirect immunofluorescence, by neutralization test, and by a haemagglutination inhibition test (HI), which was established in a practical modification for general and easy use. Among 145 individuals, of whom serum specimens had been drawn before the onset of pandemic, 19 revealed humoral immunity, i.e. titres of H1N1v neutralizing antibodies (at least 1:64). Eleven were older than 60 years, one belonged to the age group 40-59 years, three to the age group 20-39 years, and two to the age group 15-19 years. After the onset of pandemic in Frankfurt, serum specimens drawn from n = 225 randomly selected patients of our local university hospital were investigated for antibodies against H1N1v by HI, which is generally recommended for routine check of immunity. Twenty-eight individuals revealed the protecting antibody titre of at least 1:40. The age distribution had moved to mean age groups. The results fit to the incidence of influenza A/H1N1(09) disease, as confirmed by RT-PCR in patients admitted to our hospital, peaking in the younger age groups up to 30 years (second affected group: 30-40 years). While commonly used solid-phase antibody tests (like immunofluorescence) are not suitable to diagnose passed H1N1(09) infection and acquired immunity, this can be easily done by HI. Expecting the next waves of influenza A/H1N1v infections, HI testing may avoid vaccinations under special risk of severe or hidden adverse reactions.